The progress of angiogenic factors in the development of leukemias

Han, Yang; Wang, Xidi; Wang, Bingping; Jiang, Guosheng

doi:10.5582/irdr.2015.01048

Cited by 17 publications

(21 citation statements)

References 103 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These isoforms bind three tyrosine kinase receptor of VEGFR-3 (Flt-4), VEGFR-2 (KDR), and VEGFR-1 (Flt-1). 71 VEGFR-1 is mainly expressed on monocytes, HSCs, and leukemia cells while VEGFR-2 is detected on EC progenitors but VEGFR-3 is mostly confined to lymphatic EC. VEGF is secreted by several types of leukemia and contributes to disease progress via autocrine and paracrine pathways.…”

Section: The Vessel and Angiogenesis In Leukemiamentioning

confidence: 93%

Bone marrow blood vessels: normal and neoplastic niche

et al. 2016

View full text Add to dashboard Cite

Blood vessels are among the most important factors in the transport of materials such as nutrients and oxygen. This study will review the role of blood vessels in normal bone marrow hematopoiesis as well as pathological conditions like leukemia and metastasis. Relevant literature was identified by a Pubmed search (1992-2016) of English-language papers using the terms bone marrow, leukemia, metastasis, and vessel. Given that blood vessels are conduits for the transfer of nutrients, they create a favorable situation for cancer cells and cause their growth and development. On the other hand, blood vessels protect leukemia cells against chemotherapy drugs. Finally, it may be concluded that the vessels are an important factor in the development of malignant diseases.

show abstract

Section: The Vessel and Angiogenesis In Leukemiamentioning

confidence: 93%

Bone marrow blood vessels: normal and neoplastic niche

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Accordingly, the core hypothesis in angiogenesis is that the switch to the angiogenic phenotype (i.e., the angiogenic switch) of a given tumor is highly dependent on the regulation of these angiogenic factors [9,15,17,18,22]. …”

Section: Introductionmentioning

confidence: 99%

“…Folkman et al [10,16] were the first to isolate, 4 decades ago, a factor from animal tumors that could stimulate angiogenesis. Various investigators have since wondered whether tumors promote angiogenesis by secreting growth factors [17,18,19,20,21]. …”

Section: Introductionmentioning

confidence: 99%

“…Nonvascular cells such as tumor cells, inflammatory cells (i.e., macrophages, mast cells), and stromal cells (i.e., fibroblasts) can modulate angiogenesis by secreting a large number of these angiogenic factors in the malignant microenvironment [11,15,18]; the most prevalent amongst them are basic fibroblast growth factor, transforming growth factor, angiogenin, interleukin-6, hepatocyte growth factor, hypoxia-inducible factor 1, matrix metalloproteinase, vascular endothelial growth factor (VEGF), and so on [9,13,14,15,17,21,23,24,25]. Like solid tumor cells, highly proliferating plasma cells possess an angiogenic capability via the release of these angiogenic cytokines [26].…”

Section: Introductionmentioning

confidence: 99%

“…Angiogenesis itself depends on the balance between positive and negative angiogenic factors [13,14,15,17,18], whereas the interplay of tumor cells with the stroma and the endothelium through the secretion of numerous peptides seems to be beneficial for new vessel formation [10,11,18]. Accordingly, the core hypothesis in angiogenesis is that the switch to the angiogenic phenotype (i.e., the angiogenic switch) of a given tumor is highly dependent on the regulation of these angiogenic factors [9,15,17,18,22].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Microvessel Density as a Surrogate Prognostic Marker in Patients with Multiple Myeloma: A Meta-Analysis

Ntellas

Perivoliotis²,

Dadouli³

et al. 2017

Acta Haematol

View full text Add to dashboard Cite

Background/Aims: Bone marrow (BM) angiogenesis is considered a hallmark of multiple myeloma (MM) development and progression, and can be quantified with the use of microvessel density (MVD). The purpose of this study is to provide a review and a meta-analysis of the current literature regarding the prognostic value of MVD in the overall survival (OS) of MM patients. Methods: MEDLINE was screened for studies evaluating the OS of MM patients with regard to their MVD count in BM trephine. The pooled hazard ratio (HR) and its associated 95% confidence interval (CI) among MM patients with a high and low MVD count was the primary end point. Secondary outcomes included odds ratios (OR) for 12-, 36-, and 60-month survival. Results: Ten eligible trials were identified for the analysis of the primary end point and 9 for the secondary end points. Pooled HR for OS was 1.85 (95% CI: 1.25-2.73, p = 0.002). The pooled OR of survival were 1.59 (95% CI: 1.02-2.46, p = 0.04) at 12 months, 2.90 (95% CI: 1.68-5.03, p = 0.0001) at 36 months, and 3.42 (95% CI: 2.41-4.85, p < 0.00001) at 60 months, in favor of the low MVD group. Conclusion: This meta-analysis provides persuasive evidence that MVD has significant impact on the clinical outcome of MM patients.

show abstract